Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States

Mikkael Sekeres, Ahmed Hnoosh, Aylin Yucel, Dimana Miteva, Tracy Krimmel, Samantha Slaff, Derek Tang, Min Che, Yelina Wang

Blood (2025) 146 (Supplement 1): 5638.

https://doi.org/10.1182/blood-2025-5638

Published: 2025

Journal Articles

Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes

Mike Yang, Shiyun Zhu, Kenneth Poon, Raymond Lui, Gary Okano, Tony Wang, Vincent Zhang, Jingrong Yang, Samantha Slaff, Ryan Stevenson

Blood (2025) 146 (Supplement 1): 7398.

https://doi.org/10.1182/blood-2025-7398

Published: 2025

Journal Articles

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US

Idoroenyi Amanam, Chidera Agu, Siddhi Korgaonkar, Abigail Hitchens, I-Hsuan Su, Svetlana Gavrilov, Derek Tang, Rohan C. Parikh, Keith Davis, Samantha Slaff

Blood (2025) 146 (Supplement 1): 4620.

https://doi.org/10.1182/blood-2025-4620

Published: 2025

Journal Articles

Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

Claire Harrison, Jennifer Lord-Bessen, Ling Shi, Shien Guo, Aylin Yucel, Dorothy Zissler, Shalon Jones, Samantha Slaff

Blood (2024) 144 (Supplement 1): 6624.

https://doi.org/10.1182/blood-2024-198368

Published: 2024

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab Versus Other Triplet Regimens in Patients with Relapsed or Refractory Multiple Myeloma: A Population-Adjusted Indirect Treatment Comparison

Faiz Anwer, Tommy Lan, Michael Dolph, Hoora Moradian, Samantha Slaff, Yu-Hsuan Shih, Derek Tang

Blood (2023) 142 (Supplement 1): 7345.

https://doi.org/10.1182/blood-2023-173944

Published: 2023

Journal Articles

Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib

Francesco Passamonti, Rohan C. Parikh, Siddhi Korgaonkar, Manoj Chevli, Samantha Slaff, Julien Rombi, Basirat Adeyemi, Keith L. Davis, Aylin Yucel

Blood (2023) 142 (Supplement 1): 2425.

https://doi.org/10.1182/blood-2023-173420

Published: 2023

Journal Articles

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Hans C. Lee, Rafat Abonour, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Mohit Narang, James Omel, Robert M. Rifkin, Howard Terebelo, Kathleen Toomey, Lynne I. Wagner, Samantha Slaff, Dailan Danforth, Weiyuan Chung, Jasmeet Anand, Edward Yu, Derek Tang, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 13256–13258.

https://doi.org/10.1182/blood-2022-158197

Published: 2022

Journal Articles

Trends over Time in Overall Survival of Patients with Multiple Myeloma By Race/Ethnicity and By Comorbidity Status: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis

Faiz Anwer, Debbie Goldschmidt, Wenxi Tang, David R. Steffen, Binyam Yilma, Samantha Slaff

Blood (2022) 140 (Supplement 1): 10916–10917.

https://doi.org/10.1182/blood-2022-158205

Published: 2022

Journal Articles

Investigating Differences in Treatment (Tx) Patterns and Clinical Characteristics Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

Ashley Saunders, Samantha Slaff, Krishnaveni Subbiah, Tao Gu, Michelle A. Quan, Aaron S Rosenberg

Blood (2022) 140 (Supplement 1): 13252–13253.

https://doi.org/10.1182/blood-2022-158192

Published: 2022

Journal Articles

Investigating Differences in Clinical Outcomes Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

Ashley Saunders, Samantha Slaff, Krishnaveni Subbiah, Tao Gu, Kwan Ang, Aaron S Rosenberg

Blood (2022) 140 (Supplement 1): 13250–13251.

https://doi.org/10.1182/blood-2022-158187

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States

Real-world patient characteristics, treatment patterns, and outcomes in patients with myelodysplastic syndromes

Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US

Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

Pomalidomide, Dexamethasone, and Daratumumab Versus Other Triplet Regimens in Patients with Relapsed or Refractory Multiple Myeloma: A Population-Adjusted Indirect Treatment Comparison

Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Trends over Time in Overall Survival of Patients with Multiple Myeloma By Race/Ethnicity and By Comorbidity Status: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis

Investigating Differences in Treatment (Tx) Patterns and Clinical Characteristics Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

Investigating Differences in Clinical Outcomes Among Patients (Pts) Diagnosed with Multiple Myeloma (MM) Across Racial Groups

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only